ACE-031

· Acceleron Pharma, Inc. (a wholly-owned subsidiary of Merck & Co., Inc.)

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for ACE-031, covering 2011-03-23 to 2016-10-14. Get the full timeline:

Most recent: Clinical Trial Update: Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy [Phase 2]